Fenofibric acid [42017-89-0]
Referencia HY-B0760-500mg
embalaje : 500mg
Marca : MedChemExpress
Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.
Para uso exclusivo en investigación. No vendemos a pacientes.
Fenofibric acid Estructura química
No. CAS : 42017-89-0
This product is a controlled substance and not for sale in your territory.
Based on 1 publication(s) in Google Scholar
Other Forms of Fenofibric acid:
- Choline Fenofibrate In-stock
- Fenofibric acid-d6 Obtener un presupuesto
- Fenofibric acid (Standard) Obtener un presupuesto
Ver todos los productos específicos de isoformas PPAR:
Ver todos los productos específicos de isoformas COX:
Descripciòn |
Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1][2] |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cellular Effect |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In Vitro |
Fenofibric acid is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively[1]. Fenofibric acid (10, 25, 50, 75, and 100 nM) dose-dependently inhibits COX-2 enzyme, with IC50 of 48 nM[2]. Fenofibric acid (500 nM) reduces abundance of AOX1 protein in HepG2 cells[3]. Fenofibric acid (100?μM) decreases JNK1/2, c-Jun, and p38 MAPK phosphorylation, and prevents the accumulation of reactive oxygen species, endoplasmic reticulum (ER) stress and disruption of blood retinal barrier (BRB) in response to the combination of high-glucose (HG) and hypoxia in ARPE-19 cells. Fenofibric acid (100?μM) activates IGF-IR/Akt/ERK1/2-mediated survival signaling pathways in ARPE-19 cells under HG conditions and hypoxia[4]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In Vivo |
Fenofibric acid (1, 5, 10 mg/kg, p.o.) shows anti-inflammatory activity in Wistar rats with acute inflammation induced by carrageenan[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ensayo clínico |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peso molecular |
318.75 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fòrmula |
C17H15ClO4 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No. CAS |
42017-89-0 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Appearance |
Solid |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Color |
White to off-white |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SMILES |
CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(O)=O |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Envío | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Almacenamiento |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Solvente y solubilidad |
In Vitro:
DMSO : ≥ 100 mg/mL (313.73 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pureza y Documentación |
Purity: 99.94% |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Referencias |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 3.1373 mL | 15.6863 mL | 31.3725 mL | 78.4314 mL |
5 mM | 0.6275 mL | 3.1373 mL | 6.2745 mL | 15.6863 mL | |
10 mM | 0.3137 mL | 1.5686 mL | 3.1373 mL | 7.8431 mL | |
15 mM | 0.2092 mL | 1.0458 mL | 2.0915 mL | 5.2288 mL | |
20 mM | 0.1569 mL | 0.7843 mL | 1.5686 mL | 3.9216 mL | |
25 mM | 0.1255 mL | 0.6275 mL | 1.2549 mL | 3.1373 mL | |
30 mM | 0.1046 mL | 0.5229 mL | 1.0458 mL | 2.6144 mL | |
40 mM | 0.0784 mL | 0.3922 mL | 0.7843 mL | 1.9608 mL | |
50 mM | 0.0627 mL | 0.3137 mL | 0.6275 mL | 1.5686 mL | |
60 mM | 0.0523 mL | 0.2614 mL | 0.5229 mL | 1.3072 mL | |
80 mM | 0.0392 mL | 0.1961 mL | 0.3922 mL | 0.9804 mL | |
100 mM | 0.0314 mL | 0.1569 mL | 0.3137 mL | 0.7843 mL |
Fenofibric acid Related Classifications
- Cell Cycle/DNA Damage Vitamin D Related/Nuclear Receptor Metabolic Enzyme/Protease Immunology/Inflammation
- PPAR COX